0.10Open0.10Pre Close0 Volume14 Open Interest10.00Strike Price0.00Turnover974.86%IV631.88%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1725Delta0.1471Gamma13.80Leverage Ratio-0.0346Theta0.0000Rho2.38Eff Leverage0.0005Vega
Werewolf Therapeutics Stock Discussion
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Werewolf Therapeutics (HOWL) presented interim Phase 1 clinical trial results for WTX-330, their tumor-activated IL-12 prodrug, at SITC's 39th Annual Meeting. The trial enrolled 25 patients with diverse solid tumors, showing favorable tolerability and encouraging efficacy. Key findings include a confirmed partial response in a ...
4 mins ago
Werewolf Therapeutics Announces Promising New Development Candidate, Wtx-921, a First-of-Its-Kind Il-10 Indukine™ Molecule for Inflammatory Diseases
📊⚡️📊
📊⚡️📊
No comment yet